Definitive Contract 75A50123C00051
Award Date
9/22/23
Potential Completion Date
4/30/25
Potential Value
$749K
Awardee
HDT Bio Corp
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Seattle, WA 98102, USA
Solicitation Procedures
Basic Research
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $299,959 SBIR Phase I contract awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to HDT Bio Corp, a biopharmaceutical company that develops drugs and vaccines for cancer, infectious diseases, and other unmet medical needs. The contract is for research, development, testing, and manufacturing services related to HDT Bio Corp's RNA technologies, adjuvants, antibodies, nanoparticles, and other platforms to create new medical...
This firm-fixed-price SBIR Phase I contract was awarded by the Department of Health and Human Services' National Institute of Allergy and Infectious Diseases to HDT Bio Corp, a for-profit biopharmaceutical company. The $599,629 contract funds the "Rational Development of a Combination Nanoparticle Adjuvant for Influenza", which involves research and development of novel adjuvants and other medical countermeasures. HDT Bio Corp has previously served as a prime contractor on other HHS...
The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response awarded a $627,627.92 definitive contract to Nature's Toolbox Inc., doing business as Biotechnology, a subsidiary of Nature's Toolbox, Inc., for research and development of a novel, rapidly deployable RNA vaccine production platform under AOI #21 Vaccines on Demand. The firm fixed price contract will be performed in Mexico over a period of approximately two years, from April 2023 through...
HDT Bio Corp. was awarded a $11 million cost-plus-fixed-fee definitive contract by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to develop and progress HDT-301, a replicon RNA encoding SARS-CoV-2 spike protein bound to lipid inorganic nanoparticle formulation, through a Phase I clinical trial. The contract was awarded under the 2020 NIAID Omnibus Broad Agency Announcement seeking proposals to develop medical countermeasures including vaccines,...
This is a $979,538.00 Firm Fixed Price Delivery Order contract awarded to Altimmune, Inc., a for-profit organization, by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response. The contract, which was not set aside, is for the development of vaccine formulations effective against NIAID priority pathogens, evaluation of clone generation and stability, biodefense vaccine enhancement, and general biomedical research. Altimmune, Inc....
This is a $37,000 firm fixed price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services (HHS), to Protein Sciences Corp, a for-profit manufacturer, to provide purified recombinant proteins. The contract has no set-aside designation. Protein Sciences Corp has received multiple federal contract awards from HHS's Office of the Assistant Secretary for Preparedness and Response...
This is a $748,885 firm-fixed-price contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Access To Advanced Health Institute (AAHI), a nonprofit biotech research institute based in Seattle, Washington. The contract is for research and development of intranasal administration of RNA vaccines against respiratory pathogens. The contract was awarded under an Ease Broad Agency Announcement (EZ-BAA) issued by the Division of Research, Innovation, and...
This is a federal contract award to Protein Sciences Corp, a for-profit vaccine manufacturer, by the U.S. Department of Health and Human Services' (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR). The $2,146,389.00 firm fixed-price contract is a delivery order under ASPR's Pandemic Influenza Preparedness and Response 2016-2021 master IDIQ contract. The purpose of the award is for Protein Sciences to manufacture 1 bulk lot of an H7 vaccine. No set-aside designation was...
This is a cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services (HHS), to Vaxine PTY LTD, a for-profit organization located in Australia. The $18,541,473.00 contract is for the "ADVANCED DEVELOPMENT OF VACCINE CANDIDATES FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES". The contract has an end date of August 14, 2023 and was initially awarded on September 20, 2018. This contract...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services (HHS), to Advanced Bioscience Laboratories, Inc. (ABL), a for-profit manufacturer of goods. The $31,202.00 fixed-price level of effort contract is for process development of vaccine candidates, including for SARS-CoV-2. The award has an ultimate completion date of April 15, 2025. ABL has been awarded multiple indefinite...